risperidone has been researched along with Hypercholesterolemia in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 7.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 6.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| "Patients with schizophrenia or schizoaffective disorder with a body mass index ≥ 27 and non-high-density lipoprotein (non-HDL) cholesterol ≥ 130 mg/dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to switch to ari-piprazole (N=109) for 24 weeks or stay on their current medication (N=106)." | 5.15 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). ( Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 3.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "Aripiprazole treatment led to significantly more akathisia incidence in the AD group, compared with the SCZ group." | 2.48 | Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. ( Moteshafi, H; Stip, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinbrenner, A | 1 |
| Peus, V | 1 |
| Inta, D | 1 |
| Englisch, S | 1 |
| Zink, M | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Goeb, JL | 1 |
| Marco, S | 1 |
| Duhamel, A | 1 |
| Kechid, G | 1 |
| Bordet, R | 1 |
| Thomas, P | 1 |
| Delion, P | 1 |
| Jardri, R | 1 |
| Stroup, TS | 1 |
| McEvoy, JP | 2 |
| Ring, KD | 1 |
| Hamer, RH | 1 |
| LaVange, LM | 1 |
| Swartz, MS | 1 |
| Rosenheck, RA | 1 |
| Perkins, DO | 1 |
| Nussbaum, AM | 1 |
| Lieberman, JA | 2 |
| Weiden, PJ | 1 |
| Moteshafi, H | 1 |
| Stip, E | 1 |
| Lindenmayer, JP | 1 |
| Czobor, P | 1 |
| Volavka, J | 1 |
| Citrome, L | 1 |
| Sheitman, B | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Giner, V | 1 |
| Muñoz, R | 1 |
| Redón, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Management of Metabolic Problems in Patients With Schizophrenia[NCT00423878] | Phase 4 | 215 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis. (NCT00423878)
Timeframe: 24 weeks
| Intervention | mg/dL non-HDL cholesterol (Least Squares Mean) |
|---|---|
| Switch Group | -20.2 |
| Stay Group | -10.8 |
(NCT00423878)
Timeframe: Measured at Month 6
| Intervention | participants (Number) |
|---|---|
| Switch Group | 22 |
| Stay Group | 18 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
1 review available for risperidone and Hypercholesterolemia
| Article | Year |
|---|---|
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Topics: Adult; Affective Disorders, Psychotic; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; | 2012 |
2 trials available for risperidone and Hypercholesterolemia
5 other studies available for risperidone and Hypercholesterolemia
| Article | Year |
|---|---|
Risperidone-associated increase in triglyceride levels.
Topics: Adult; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Humans; Hypercholesterol | 2009 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
[Metabolic side effects of risperidone in early onset schizophrenia].
Topics: Adolescent; Age Factors; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Hypercholeste | 2010 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; | 2011 |
Risperidone and severe cerivastatin-induced rhabdomyolysis.
Topics: Aged; Antipsychotic Agents; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2002 |